# Midatech Pharma granted FDA Fast Track designation for MTX110

- Link: https://www.directorstalkinterviews.com/midatech-pharma-granted-fda-fast-track-designation-for-mtx110/4121067062
- Published: 2022-06-01T12:31:49+01:00
- Author: Amilia Stone

**Midatech Pharma PLC **(LON:MTPH), an R&D biotechnology company focused on improving
the bio-delivery and biodistribution of medicines, has announced that upon submitting
an application to the U.S. Food and Drug Administration, its development programme
of MTX110 for the treatment of recurrent glioblastoma has been granted Fast Track
designation by the agency.

Fast Track is a process designed to facilitate the development and expedite the 
review of treatments for serious conditions and that potentially address unmet medical
needs. Drugs that are granted this designation are given the opportunity for more
frequent interactions with the FDA, as well as potential pathways for expedited 
approval.

> **Commenting, Dmitry Zamoryakhin, CSO of Midatech Pharma, said:** “rGBM is a devastating
> cancer marked by short survival rate and universal recurrence. Receiving Fast 
> Track designation for MTX110 is an important milestone for the development of 
> the drug as it demonstrates the need for novel and effective treatment options
> for this currently universally fatal disease. MTX110, our water-soluble formulation
> of Panobinostat, will soon start recruitment into a Company-sponsored Phase I 
> study in patients with recurrent GBM.”

Share on:
